Wubben TJ, et al. - Researchers performed this retrospective, multicenter, case series to illustrate that patients with diabetic retinopathy who are treated solely with anti-vascular endothelial growth factor (VEGF) therapy and who have an interruption in treatment may experience marked disease progression with potentially devastating visual consequences. Thirteen eyes have been identified from 12 patients with type 2 diabetes. Intercurrent illness, noncompliance, and financial issues were included reasons for treatment interruption. Follow-up complications included vitreous hemorrhage, neovascular glaucoma, and traction retinal detachment. Unintentional treatment interruptions can lead in irreversible blindness in patients with diabetic retinopathy, particularly PDR, who are treated with anti-VEGF therapy alone.